Outlook Therapeutics Announces U.S. Price for LYTENAVA — $485/vial

What Happened Outlook Therapeutics, Inc. (OTLK) announced in an Item 8.01 filing on September 18, 2026, that on September 16, 2026 it established the U.S. wholesale acquisition cost (WAC) for its drug LYTENAVA™ at $485 per vial. The announcement was reported in a Form 8-K under "Other Events."

Key Details

• Company: Outlook Therapeutics, Inc. (OTLK).
• Product: LYTENAVA™.
• Price set: Wholesale acquisition cost (WAC) = $485 per vial.
• Filing: Form 8-K, Item 8.01, filed September 18, 2026 (event dated September 16, 2026).

Why It Matters Setting a WAC provides a reference price that can influence hospital and pharmacy purchase costs, insurer reimbursement negotiations, and revenue modeling. For investors, the $485/vial list price is a concrete input for estimating potential sales revenue, market positioning, and payer discussions; however, actual net revenue will depend on discounts, rebates, and negotiated reimbursement rates. The 8-K reports the pricing decision but does not provide sales forecasts, launch timing details, or reimbursement commitments.